| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e9e0b17a7397b2f1b810b713a0e7651 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6921
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6949
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2018-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_496bd92bbc1fd1691e83de1a7a1488fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2274e3f35f3de827838e963315731cbc |
| publicationDate |
2019-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10278988-B2 |
| titleOfInvention |
Reducing the proliferation of carcinoma cells by administration of a poly-oxygenated metal hydroxide |
| abstract |
A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O 2 ) molecules. The carcinoma cells may comprise prostrate carcinoma (22Rv1). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid. |
| priorityDate |
2016-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |